Connection

Co-Authors

This is a "connection" page, showing publications co-authored by NAOTO T UENO and MIEN-CHIE HUNG.
Connection Strength

0.831
  1. E1A is an oncogene and may immortalize normal cells, especially in combination with other oncoproteins. J Clin Oncol. 2001 Nov 01; 19(21):4183-4.
    View in: PubMed
    Score: 0.211
  2. Growth suppression of low HER-2/neu-expressing breast cancer cell line MDA-MB-435 by tyrosine kinase inhibitor emodin. Oncol Rep. 1996 May; 3(3):509-11.
    View in: PubMed
    Score: 0.144
  3. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res. 2013 Nov 01; 73(21):6516-25.
    View in: PubMed
    Score: 0.120
  4. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res. 2009 Nov 01; 15(21):6639-48.
    View in: PubMed
    Score: 0.091
  5. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther. 2009 Aug; 8(8):2375-82.
    View in: PubMed
    Score: 0.090
  6. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res. 2005 Sep 15; 65(18):8406-13.
    View in: PubMed
    Score: 0.069
  7. Osteoprogenitor-GMP crosstalk underpins solid tumor-induced systemic immunosuppression and persists after tumor removal. Cell Stem Cell. 2023 05 04; 30(5):648-664.e8.
    View in: PubMed
    Score: 0.058
  8. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. J Exp Clin Cancer Res. 2014 Jul 23; 33:58.
    View in: PubMed
    Score: 0.032
  9. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004 Jun 01; 64(11):3981-6.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.